Introduction: Diabetes mellitus (DM) is a metabolic disorder associated with both microvascular and macrovascular complications. Mean platelet volume (MPV) is a marker of platelet activity, which plays a major role in the development of vascular complications of DM. The aim of this study is to compare the MPV levels before and after the decrease of glycated hemoglobin (HbA) levels in a large diabetic population.
Material And Methods: This was a retrospective study conducted on type 2 diabetic patients from the outpatient clinic for 1 year between 2014 and 2015 with the participation of 595 diabetic patients.
Results: When we compared the basal and post-treatment values, a significant decrease of MPV and HbA levels was found (HbA: 9.41 ±1.98% vs. 7.43 ±1.29%, < 0.001; MPV: 9.11 ±1.42 vs. 8.17 ±1.04, < 0.001). There was also a positive correlation between the mean changes of MPV and HbA levels after the treatment (ΔMPV: 0.93 ±0.96 vs. ΔHbA: 1.96 ±1.43; = 0.005, = 0.115). When the participants were divided into two groups according to their basal HbA levels (group A: HbA ≤ 6.5% and group B: HbA > 6.5%), it was clearly seen that improvement of glucose levels led to a significant decrease in MPV levels in both groups.
Conclusions: The results of this study show that better glycemic control is associated with a significant decrease of MPV levels, regardless of whether the treatment modality is insulin or oral antidiabetic.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510507 | PMC |
| http://dx.doi.org/10.5114/aoms.2016.61900 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.
Diabetologia
January 2025
Internal Medicine Department, Endocrine Division (SEMPR), Universidade Federal do Paraná, Curitiba, Brazil.
Aims/hypothesis: COMBINE 2 assessed the efficacy and safety of once-weekly IcoSema (a combination therapy of basal insulin icodec and semaglutide) vs once-weekly semaglutide (a glucagon-like peptide-1 analogue) 1.0 mg in individuals with type 2 diabetes inadequately managed with GLP-1 receptor agonist (GLP-1 RA) therapy, with or without additional oral glucose-lowering medications.
Methods: This 52 week, randomised, multicentre, open-label, parallel group, Phase IIIa trial was conducted across 121 sites in 13 countries/regions.
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.
Lancet Diabetes Endocrinol
January 2025
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Electronic address:
Background: Data on the effect of mineralocorticoid receptor antagonist therapy on HbA levels and new-onset diabetes are conflicting. We aimed to examine the effect of oral finerenone, compared with placebo, on incident diabetes in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF) trial.
Methods: In this randomised, double-blind, placebo-controlled trial, 6001 participants with heart failure with New York Heart Association functional class II-IV, left ventricular ejection fraction 40% or higher, evidence of structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide levels were randomly assigned to finerenone or placebo, administered orally.
Predicting Mortality and Hospitalization in Heart Failure With Preserved Ejection Fraction by Using Machine Learning.
JACC Asia
December 2024
Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, and Chang Gung University College of Medicine, Taoyuan, Taiwan.
Background: Few studies have incorporated echocardiography and laboratory data to predict clinical outcomes in heart failure with preserved ejection fraction (HFpEF).
Objectives: This study aimed to use machine learning to find predictors of heart failure (HF) hospitalization and cardiovascular (CV) death in HFpEF.
Methods: From the Chang Gung Research Database in Taiwan, 6,092 HFpEF patients (2,898 derivation, 3,194 validation) identified between 2008 and 2017 were followed until 2019.
The impact of fasting on cardiovascular risk control in patients with metabolic dysfunction-associated steatotic liver disease.
Prz Gastroenterol
September 2023
Departament of Civilization Diseases, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, Warsaw, Poland.
Introduction: Optimal control of cardiovascular risk factors remains challenging in non-classical patient groups, including those with metabolic dysfunction-associated steatotic liver disease (MASLD). Dietary restrictions are among the interventions that may be helpful in such cases.
Aim: To evaluate if the declared type of fasting influences the most common cardiovascular risk factor control in patients with MASLD.
The multifaceted function of FoxO1 in pancreatic β-cell dysfunction and insulin resistance: Therapeutic potential for type 2 diabetes.
Life Sci
January 2025
School of Life Science and Technology, Shandong Second Medical University, Weifang 261021, China. Electronic address:
The forkhead box O1 (FOXO1), the first discovered member of the FoxO family, is a critical transcription factor predominantly found in insulin-secreting and insulin-sensitive tissues. In the pancreas of adults, FoxO1 expression is restricted to islet β cells. We determined that in human islet microarray datasets, FoxO1 expression is higher than other FoxO transcription factors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!